|
Consensus recommendations |
Grade |
|
All individuals with cirrhosis should be enrolled in HCC screening programs. |
A1 |
| HCC surveillance should involve liver ultrasound + serum alpha-fetoprotein measurement performed every 6 months. |
A1 |
|
All individuals with cirrhosis should be offered DAA treatment for HCV infection. |
A1 |
|
HCC surveillance should continue long term after SVR in people with cirrhosis. |
A1 |
|
Patients with HCC should be considered for DAA therapy. |
A1 |
|
Decisions about the timing of DAA therapy for HCV in people with active HCC should be made with a multidisciplinary team. |
B1 |
|
People with cirrhosis and prior HCC should be closely monitored for HCC recurrence during and after DAA therapy for HCV infection. |
B2 |
|
HCC surveillance for all individuals with no cirrhosis is not cost-effective. |
A1 |